Bain Capital Life Sciences Investors, LLC Long-Term Concentrated

CIK: 0001703031 · Show all filings

Period: Q1 2019 (← Previous) (Next →)

Filing Date: May 15, 2019

Total Value ($000): $250,119 (100.0% shares, 0.0% debt)

Holdings (6)

— DICERNA PHARMACEUTICALS INC 52.3%

Value ($000) $130,828 Shares 8,930,237 Est. Cost $9.03 Unrealized —

REPL REPLIMUNE GROUP INC 17.3%

Value ($000) $43,209 Shares 2,838,968 Est. Cost $17.53 Unrealized -28.9%

IFRX INFLARX NV 11.1%

Value ($000) $27,688 Shares 732,670 Est. Cost $17.97 Unrealized +107.4%

— MARINUS PHARMACEUTICALS INC 8.4%

Value ($000) $21,079 Shares 5,042,735 Est. Cost $7.04 Unrealized —

— SOLID BIOSCIENCES INC 7.3%

Value ($000) $18,303 Shares 1,989,444 Est. Cost $7.50 Unrealized —

— APTINYX INC 3.6%

Value ($000) $9,012 Shares 2,225,092 Est. Cost $24.17 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	DICERNA PHARMACEUTICALS INC	8,930,237	$130,828	52.3%	$9.03	—	COM	253031108
REPL	REPLIMUNE GROUP INC	2,838,968	$43,209	17.3%	$17.53	-28.9%	COM	76029N106
IFRX	INFLARX NV	732,670	$27,688	11.1%	$17.97	+107.4%	COM	N44821101
—	MARINUS PHARMACEUTICALS INC	5,042,735	$21,079	8.4%	$7.04	—	COM	56854Q101
—	SOLID BIOSCIENCES INC	1,989,444	$18,303	7.3%	$7.50	—	COM	83422E105
—	APTINYX INC	2,225,092	$9,012	3.6%	$24.17	—	COM	03836N103